ArticleScientific reports2020
Plasma β-III tubulin, neurofilament light chain and glial fibrillary acidic protein are associated with neurodegeneration and progression in schizophrenia.
Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05257720 (Evaluation of the Role of Neurodegeneration in Treatment Resistant Schizophrenia With GFAP and S100B), which is not on this map. Cited by 23 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of the Role of Neurodegeneration in Treatment Resistant Schizophrenia With GFAP and S100B
Who cites it
23 citing papers in PubMed, 2 syntheses or guidelines pooled it, 38 citations in OpenAlex.
- Neurofilament Light Protein as a Biomarker in Severe Mental Disorders: A Systematic Review.International journal of molecular sciences · 2024Pooled it
- The role of glial cells in mental illness: a systematic review on astroglia and microglia as potential players in schizophrenia and its cognitive and emotional aspects.Frontiers in cellular neuroscience · 2024Pooled it
- Therapeutic efficacy of quetiapine combined with magnesium valproate in schizophrenia: Impact on serum BDNF and GFAP levels.Medicine · 2025Trial
- Blood ATX(N) Biomarkers and Cognitive Dysfunction in Severe Mental Illnesses.International journal of molecular sciences · 2026Review
- Integrating cellular and soluble immune signatures of major depression with and without recent suicide attempts.Translational psychiatry · 2025Article
- Pilot study of cerebrospinal fluid biomarkers reveals inflammatory changes in patients with paranoid schizophrenia.Scientific reports · 2025Article
- Transient Global Amnesia (TGA): Is It Really Benign? A Pilot Study on Blood Biomarkers.International journal of molecular sciences · 2025Article
- Glial cell deficits are a key feature of schizophrenia: implications for neuronal circuit maintenance and histological differentiation from classical neurodegeneration.Molecular psychiatry · 2025Review
- Plasma neurofilament light chain mediates the effect of subsyndromal symptomatic depression on cognitive decline in older adults.Frontiers in aging neuroscience · 2025Article
- Biomarkers Unveiling the Interplay of Mind, Nervous System, and Immunity.Methods in molecular biology (Clifton, N.J.) · 2025Review
- Introducing neurofilament light chain measure in psychiatry: current evidence, opportunities, and pitfalls.Molecular psychiatry · 2024Review
- Neurofilament light-chain (NfL) and 18 kDa translocator protein in early psychosis and its putative high-risk.Brain, behavior, & immunity - health · 2024Article
- Associations between structural brain changes and blood neurofilament light chain protein in treatment-resistant schizophrenia.medRxiv : the preprint server for health sciences · 2024Article
- Neurofilament light chain plasma levels in major depressive disorder: a brief research report.Frontiers in psychiatry · 2024Article
- Biomarker Methodologies: A NIMH Perspective.Advances in neurobiology · 2024Review
- Association Between Retinal Features From Multimodal Imaging and Schizophrenia.JAMA psychiatry · 2023Article
- Neurodegeneration Markers in the Cerebrospinal Fluid of 100 Patients with Schizophrenia Spectrum Disorder.Schizophrenia bulletin · 2023Article
- Genetic mechanisms of 184 neuro-related proteins in human plasma.medRxiv : the preprint server for health sciences · 2023Article
- Plasma neurofilament light chain protein is not increased in forensic psychiatric populations: a pilot study.Frontiers in psychiatry · 2023Article
- The 2022 Lady Estelle Wolfson lectureship on neurofilaments.Journal of neurochemistry · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Schizophrenia is a progressive disorder characterized by multiple psychotic relapses. After every relapse, patients may not fully recover, and this may lead to a progressive loss of functionality. Pharmacological treatment represents a key factor to minimize the biological, psychological and psychosocial impact of the disorder. The number of relapses and the duration of psychotic episodes induce a potential neuronal damage and subsequently, neurodegenerative processes. Thus, a comparative study was performed, including forty healthy controls and forty-two SZ patients divided into first-episode psychosis (FEP) and chronic SZ (CSZ) subgroups, where the CSZ sub group was subdivided by antipsychotic treatment. In order to measure the potential neuronal damage, plasma levels of β-III tubulin, neurofilament light chain (Nf-L), and glial fibrillary acidic protein (GFAP) were performed. The results revealed that the levels of these proteins were increased in the SZ group compared to the control group (P < 0.05). Moreover, multiple comparison analysis showed highly significant levels of β-III tubulin (P = 0.0002), Nf-L (P = 0.0403) and GFAP (P < 0.015) in the subgroup of CSZ clozapine-treated. In conclusion, β-III tubulin, Nf-L and GFAP proteins may be potential biomarkers of neurodegeneration and progression in SZ.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.